FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3018925596> ?p ?o ?g. }

• W3018925596 endingPage "2452" @default.
• W3018925596 startingPage "2450" @default.
• W3018925596 abstract "We appreciate the comments and perspective expressed by Dr. Strauss regarding our recent pandemic contingency guidance,1Shaker M.S. Oppenheimer J. Grayson M. Stukus D. Hartog N. Hsieh E.W.Y. et al.COVID-19: pandemic contingency planning for the allergy and immunology clinic.J Allergy Clin Immunol Pract. 2020; 8: 1477-1488Abstract Full Text Full Text PDF PubMed Scopus (229) Google Scholar and we agree that in the setting of acute severe asthma or impending respiratory failure, both nebulized albuterol and subcutaneous terbutaline are important clinical considerations. Although evidence suggests that inhaled albuterol through a metered dose inhaler can be as effective as nebulized albuterol, alternative bronchodilator delivery may be needed in some situations.2Amirav I. Newhouse M.T. Metered-dose inhaler accessory devices in acute asthma: efficacy and comparison with nebulizers: a literature review.Arch Pediatr Adolesc Med. 1997; 151: 876-882Crossref PubMed Scopus (84) Google Scholar,3Dhuper S. Chandra A. Ahmed A. Bista S. Moghekar A. Verma R. et al.Efficacy and cost comparisons of bronchodilatator administration between metered dose inhalers with disposable spacers and nebulizers for acute asthma treatment.J Emerg Med. 2011; 40: 247-255Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar Although subcutaneous terbutaline may be an option, if nebulized therapy is required due to patient impairment and ineffective drug delivery by the metered dose inhaler, it would be an appropriate consideration if felt to be essential in patient management. In this context, for a patient with potential SARS-CoV-2 infection, it would be appropriate to consider administering nebulized therapy in a negative pressure room with appropriate airborne precautions—complete personal protective equipment (PPE) including an N95 respirator.1Shaker M.S. Oppenheimer J. Grayson M. Stukus D. Hartog N. Hsieh E.W.Y. et al.COVID-19: pandemic contingency planning for the allergy and immunology clinic.J Allergy Clin Immunol Pract. 2020; 8: 1477-1488Abstract Full Text Full Text PDF PubMed Scopus (229) Google Scholar In the setting of acute severe asthma, it is important to ensure availability of emergency medical services and/or additional intensive care resources that may be required for patient management, including supplemental oxygen, aggressive bronchodilator therapies (both intramuscular and intravenous beta-agonists, anticholinergics, and other smooth muscle inhibitors including magnesium sulfate), anti-inflammatory medications including early administration of corticosteroids, and supportive measures such as noninvasive positive pressure ventilation and helium-oxygen gas mixtures.4Toy D. Braga M.S. Greenhawt M. Shaker M. An update on allergic emergencies.Curr Opin Pediatr. 2019; 31: 426-432Crossref PubMed Scopus (1) Google Scholar Terbutaline is a beta-agonist that preferentially stimulates beta-2 receptors in the bronchi to a greater degree than beta-1 receptors in the heart. Although terbutaline is effective at a dose of 0.5 mg (0.5 mL) subcutaneously in adult patients presenting with acute severe asthma, it is also notable that epinephrine at a dose of 0.5 mg (0.5 mL) has been shown to have similar benefit with a comparable adverse effect profile.5Spiteri M.A. Millar A.B. Pavia D. Clarke S.W. Subcutaneous adrenaline versus terbutaline in the treatment of acute severe asthma.Thorax. 1988; 43: 19-23Crossref PubMed Scopus (28) Google Scholar,6Amory D.W. Burnham S.C. Cheney Jr., F.W. Comparison of the cardiopulmonary effects of subcutaneously administered epinephrine and terbutaline in patients with reversible airway obstruction.Chest. 1975; 67: 279-286Crossref PubMed Scopus (27) Google Scholar Dosing of subcutaneous terbutaline and subcutaneous epinephrine is similar (0.01 mg/kg/dose), with an adult dose of 0.25 mg for terbutaline and 0.3 to 0.5 mg for epinephrine every 20 minutes for 3 doses recommended by the 3rd Expert Panel Report (EPR3).7Lexicomp..https://www.wolterskluwercdi.com/lexicomp-online/Google Scholar,8National Heart, Lung, and Blood InstituteGuidelines for the Diagnosis and Management of Asthma (EPR-3)..https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthmaGoogle Scholar Notably, when administered subcutaneously, evidence suggests that terbutaline loses its beta-selectivity and offers little advantage over epinephrine,6Amory D.W. Burnham S.C. Cheney Jr., F.W. Comparison of the cardiopulmonary effects of subcutaneously administered epinephrine and terbutaline in patients with reversible airway obstruction.Chest. 1975; 67: 279-286Crossref PubMed Scopus (27) Google Scholar which may be more readily available in many office settings; however, terbutaline subcutaneously may be preferred over subcutaneous epinephrine in pregnancy.9Papiris S. Kotanidou A. Malagari K. Roussos C. Clinical review: severe asthma.Crit Care. 2002; 6: 30-44Crossref PubMed Scopus (166) Google Scholar In addition, if both subcutaneous epinephrine and terbutaline are available, terbutaline may be preferred as its effect on forced expiratory volume in 1 second and forced vital capacity may be more pronounced and of longer duration as a result of its slower rate of inactivation, because it is not metabolized by either catechol-o-methyl transferase or monoamine oxidase as is epinephrine.6Amory D.W. Burnham S.C. Cheney Jr., F.W. Comparison of the cardiopulmonary effects of subcutaneously administered epinephrine and terbutaline in patients with reversible airway obstruction.Chest. 1975; 67: 279-286Crossref PubMed Scopus (27) Google Scholar The recently released GINA guidelines10Global Initiative for AsthmaGINA Report, Global Strategy for Asthma Management and Prevention 2020..https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdfDate: 2020Google Scholar and EPR38National Heart, Lung, and Blood InstituteGuidelines for the Diagnosis and Management of Asthma (EPR-3)..https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthmaGoogle Scholar recommend nebulized or inhaled short-acting beta-agonists for the initial treatment of acute asthma exacerbation; EPR3 stated that injected epinephrine or terbutaline had “no proven advantage” compared with aerosol therapy.8National Heart, Lung, and Blood InstituteGuidelines for the Diagnosis and Management of Asthma (EPR-3)..https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthmaGoogle Scholar Properly designed studies demonstrating superior therapeutic utility of terbutaline for acute asthma are required to alter this recommendation; however, in the setting of the current SARS-CoV-2 pandemic and the need to implement droplet and situational airborne precautions, administration of injected bronchodilator therapy may merit consideration. The benefits of using subcutaneous terbutaline or subcutaneous epinephrine in acute severe asthma may outweigh the increased risks of SARS-CoV-2 infection by nebulizer therapy, especially in an increasingly common scenario of PPE shortages throughout North America. Importantly, when delivering bronchodilator therapy in the setting of acute asthma, supplemental oxygen may be needed because approximately one-third of patients may experience a decrease in PaO2, and patients who are already hypoxic may be at greater risk due to ventilation-perfusion mismatch.6Amory D.W. Burnham S.C. Cheney Jr., F.W. Comparison of the cardiopulmonary effects of subcutaneously administered epinephrine and terbutaline in patients with reversible airway obstruction.Chest. 1975; 67: 279-286Crossref PubMed Scopus (27) Google Scholar In this setting, beta-agonists may increase perfusion relative to ventilation through cardiac output and pulmonary vasodilation.6Amory D.W. Burnham S.C. Cheney Jr., F.W. Comparison of the cardiopulmonary effects of subcutaneously administered epinephrine and terbutaline in patients with reversible airway obstruction.Chest. 1975; 67: 279-286Crossref PubMed Scopus (27) Google Scholar In the context of supplemental oxygen therapy, recommendations for PPE for patients with suspected SARS-CoV-2 infection would also apply.1Shaker M.S. Oppenheimer J. Grayson M. Stukus D. Hartog N. Hsieh E.W.Y. et al.COVID-19: pandemic contingency planning for the allergy and immunology clinic.J Allergy Clin Immunol Pract. 2020; 8: 1477-1488Abstract Full Text Full Text PDF PubMed Scopus (229) Google Scholar During the COVID-19 pandemic, each clinician must treat the patient in front of him or her, managing each unique situation in its appropriate context. Although subcutaneous beta-agonists may have a role in managing some asthma exacerbations during the pandemic, COVID-19 is not an absolute contraindication to any medication or management strategy urgently needed in delivering optimal care. Still, Dr. Strauss highlights an important and often overlooked aspect in the management of acute asthma exacerbations and we greatly appreciate this insight. Subcutaneous terbutaline as an alternative to aerosolized albuterolThe Journal of Allergy and Clinical Immunology: In PracticeVol. 8Issue 7PreviewIn their well-written and comprehensive article regarding contingency planning for the COVID-19 epidemic, Shaker et al1 discuss the treatment of exacerbation of asthma. During the COVID-19 epidemic, asthmatics will continue to have exacerbations, frequently requiring emergency care in a physician's office, an urgent care center, or an emergency department of a hospital. Full-Text PDF" @default.
• W3018925596 created "2020-05-01" @default.
• W3018925596 creator A5000103949 @default.
• W3018925596 creator A5003237628 @default.
• W3018925596 creator A5004055251 @default.
• W3018925596 creator A5006861591 @default.
• W3018925596 creator A5008720480 @default.
• W3018925596 creator A5016112377 @default.
• W3018925596 creator A5018314993 @default.
• W3018925596 creator A5029505020 @default.
• W3018925596 creator A5032500709 @default.
• W3018925596 creator A5036900631 @default.
• W3018925596 creator A5043556111 @default.
• W3018925596 creator A5043721923 @default.
• W3018925596 creator A5046380497 @default.
• W3018925596 creator A5053450433 @default.
• W3018925596 creator A5054301538 @default.
• W3018925596 creator A5065706943 @default.
• W3018925596 creator A5070785703 @default.
• W3018925596 creator A5075398067 @default.
• W3018925596 creator A5078291592 @default.
• W3018925596 creator A5087427572 @default.
• W3018925596 creator A5090405389 @default.
• W3018925596 date "2020-07-01" @default.
• W3018925596 modified "2023-10-17" @default.
• W3018925596 title "Reply to “Subcutaneous terbutaline as an alternative to aerosolized albuterol”" @default.
• W3018925596 cites W1561496887 @default.
• W3018925596 cites W1985021264 @default.
• W3018925596 cites W2036146446 @default.
• W3018925596 cites W2093092614 @default.
• W3018925596 cites W2093272023 @default.
• W3018925596 cites W2929090888 @default.
• W3018925596 cites W3014007058 @default.
• W3018925596 doi "https://doi.org/10.1016/j.jaip.2020.04.016" @default.
• W3018925596 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7174169" @default.
• W3018925596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32340824" @default.
• W3018925596 hasPublicationYear "2020" @default.
• W3018925596 type Work @default.
• W3018925596 sameAs 3018925596 @default.
• W3018925596 citedByCount "1" @default.
• W3018925596 countsByYear W30189255962023 @default.
• W3018925596 crossrefType "journal-article" @default.
• W3018925596 hasAuthorship W3018925596A5000103949 @default.
• W3018925596 hasAuthorship W3018925596A5003237628 @default.
• W3018925596 hasAuthorship W3018925596A5004055251 @default.
• W3018925596 hasAuthorship W3018925596A5006861591 @default.
• W3018925596 hasAuthorship W3018925596A5008720480 @default.
• W3018925596 hasAuthorship W3018925596A5016112377 @default.
• W3018925596 hasAuthorship W3018925596A5018314993 @default.
• W3018925596 hasAuthorship W3018925596A5029505020 @default.
• W3018925596 hasAuthorship W3018925596A5032500709 @default.
• W3018925596 hasAuthorship W3018925596A5036900631 @default.
• W3018925596 hasAuthorship W3018925596A5043556111 @default.
• W3018925596 hasAuthorship W3018925596A5043721923 @default.
• W3018925596 hasAuthorship W3018925596A5046380497 @default.
• W3018925596 hasAuthorship W3018925596A5053450433 @default.
• W3018925596 hasAuthorship W3018925596A5054301538 @default.
• W3018925596 hasAuthorship W3018925596A5065706943 @default.
• W3018925596 hasAuthorship W3018925596A5070785703 @default.
• W3018925596 hasAuthorship W3018925596A5075398067 @default.
• W3018925596 hasAuthorship W3018925596A5078291592 @default.
• W3018925596 hasAuthorship W3018925596A5087427572 @default.
• W3018925596 hasAuthorship W3018925596A5090405389 @default.
• W3018925596 hasBestOaLocation W30189255961 @default.
• W3018925596 hasConcept C126322002 @default.
• W3018925596 hasConcept C177713679 @default.
• W3018925596 hasConcept C2776042228 @default.
• W3018925596 hasConcept C2776954882 @default.
• W3018925596 hasConcept C2780252434 @default.
• W3018925596 hasConcept C42219234 @default.
• W3018925596 hasConcept C71924100 @default.
• W3018925596 hasConcept C82085835 @default.
• W3018925596 hasConceptScore W3018925596C126322002 @default.
• W3018925596 hasConceptScore W3018925596C177713679 @default.
• W3018925596 hasConceptScore W3018925596C2776042228 @default.
• W3018925596 hasConceptScore W3018925596C2776954882 @default.
• W3018925596 hasConceptScore W3018925596C2780252434 @default.
• W3018925596 hasConceptScore W3018925596C42219234 @default.
• W3018925596 hasConceptScore W3018925596C71924100 @default.
• W3018925596 hasConceptScore W3018925596C82085835 @default.
• W3018925596 hasFunder F4320307765 @default.
• W3018925596 hasFunder F4320307770 @default.
• W3018925596 hasFunder F4320307773 @default.
• W3018925596 hasFunder F4320307776 @default.
• W3018925596 hasFunder F4320307778 @default.
• W3018925596 hasFunder F4320307781 @default.
• W3018925596 hasFunder F4320308970 @default.
• W3018925596 hasFunder F4320311600 @default.
• W3018925596 hasFunder F4320316412 @default.
• W3018925596 hasFunder F4320316473 @default.
• W3018925596 hasFunder F4320327303 @default.
• W3018925596 hasFunder F4320332177 @default.
• W3018925596 hasFunder F4320332193 @default.
• W3018925596 hasFunder F4320333100 @default.
• W3018925596 hasFunder F4320337355 @default.
• W3018925596 hasFunder F4320337362 @default.
• W3018925596 hasIssue "7" @default.
• W3018925596 hasLocation W30189255961 @default.

• next